Assessing of neonatal pertussis vaccination using the mouse intranasal challenge mode

BOTTERO, D.; MARTIN AISPURO, P.; HOZBOR, D.

Brussels

Simposio; 12th International Symposium on Bordetella April 9th-12th, 2019 ? Brussels, Belgium; 2019

Faculty of Medicine Université Libre de Bruxelles

Despite 70 years of available vaccines against pertussis, the disease is nowadays considered reemergent. Individuals of all ages are succeptible to pertussis infection, but the most vulnerable group is newborns between birth and the first vaccine dose (6-8 weeks) in which most complications, hospitalization rate and fatal cases ocurr. Maternal immunizations (MI)seems to be the best strategy to reduce the disease burden in newborns. However, MI-coverage is not optimal because obstetricians do not always recomend MI, or not all women perform pregnancy controls in which they have thw opportunity to get vaccinated. As 99% of deliveries are performed with medical attention, neonatal immunization (NI) could be considered either as an alternative or a complementary strategy. Here, using the intranasal challenge model, we evaluated the protective capacity of NI in 7day-old either naive or with maternal -acquired-immunity. Commercial acellular (aP) and cellular vaccines (wP) as well as a novel formulation based on outermembrane vesicles (OMVP) were tested.